Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases ; volume:19 ; number:1 ; day:12 ; month:11 ; year:2019 ; pages:1-9 ; date:12.2019
BMC pulmonary medicine ; 19, Heft 1 (12.11.2019), 1-9, 12.2019
- Urheber
-
Torrisi, Sebastiano Emanuele
Kahn, Nicolas
Wälscher, Julia
Sarmand, Nilab
Polke, Markus
Kehler, Lars
Eichinger, Monika
Heußel, Claus Peter
Palmucci, Stefano
Sambataro, Francesca Maria
Sambataro, Gianluca
Sambataro, Domenico
Vancheri, Carlo
Kreuter, Michael
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-019-0937-0
- URN
-
urn:nbn:de:101:1-2020031001471005986283
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Torrisi, Sebastiano Emanuele
- Kahn, Nicolas
- Wälscher, Julia
- Sarmand, Nilab
- Polke, Markus
- Kehler, Lars
- Eichinger, Monika
- Heußel, Claus Peter
- Palmucci, Stefano
- Sambataro, Francesca Maria
- Sambataro, Gianluca
- Sambataro, Domenico
- Vancheri, Carlo
- Kreuter, Michael
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF
Expanding horizons: lung transplantation for non-IPF interstitial lung diseases
Ipf, Der Ipf
Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
IPF
IPF
The natural history of progressive fibrosing interstitial lung diseases
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF
Expanding horizons: lung transplantation for non-IPF interstitial lung diseases
Ipf, Der Ipf
Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
IPF
IPF
The natural history of progressive fibrosing interstitial lung diseases
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF
Expanding horizons: lung transplantation for non-IPF interstitial lung diseases
Ipf, Der Ipf
Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
IPF
IPF